Urogen pharma announces inducement grants under nasdaq listing rule 5635(c)(4)

Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“rsus”) to 7 new employees in connection with their employment with urogen. these new team members will support the ongoing commercialization of jelmyto® (mitomycin) for pyelocalyceal solution, urogen's first approved product, and the co.
NDAQ Ratings Summary
NDAQ Quant Ranking